Company Overview
- Website
- deverratx.com
- Phone
- (206) 519-5300
- Employees
- 10
- Industry
- BioTech/Drugs
- SIC Code
-
8731 - Commercial Physical and Biological Research
Financials & Stats
Revenue
$10B
Recent News & Media
Natural born killers: harnessing innate immunity to fight severe infections
- Apr 16, 2025
- fredhutch.org
Coeptis Therapeutics Secures Worldwide Development and
- Mar 11, 2025
- globenewswire.com
Dilanubicel by Deverra Therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
- Dec 30, 2024
- pharmaceutical-technology.com
Coeptis Therapeutics Announces Reverse Stock Split
- Dec 27, 2024
- prnewswire.com
Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use
- Oct 24, 2024
- prnewswire.com
Deverra Therapeutics Granted FDA Fast Track Designation for DVX101 (Dilanubicel) for the Treatment of Acute Myeloid Leukemia
- Apr 24, 2024
- firstwordpharma.com
Companies Similar to Deverra Therapeutics
Analyze industry trends and opportunities by examining competitors and companies comparable to Deverra Therapeutics, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 10M | 59 | Boston, MA | ||
| 10M | 27 | Cambridge, MA | 2010 | |
| 10M | 23 | Waltham, MA | 1999 | |
| 10M | 2 | Boston, MA | ||
| 10M | 46 | Woburn, MA |